Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NR1H2 | P55055 | 6/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.41 |
| ▸ | RXRA | P19793 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 2/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539220 | 0.86 | MAPK1 (0.46) | MAPK1NR1H2NR1H3RXRAGPR119 | |
| SCHEMBL1747677 | 0.81 | POLB (0.36) | MAPK1GPR119 | |
| SCHEMBL6268801 | 0.79 | NR1H2 (0.48) | MAPK1NR1H2NR1H3RXRAGPR119 | |
| SCHEMBL17596585 | 0.78 | MAPK1 (0.41) | MAPK1NR1H2GPR119 | |
| SCHEMBL17596640 | 0.78 | MAPK1 (0.41) | MAPK1NR1H2GPR119 | |
| SCHEMBL31566636 | 0.76 | NR1H2 (0.44) | NR1H2NR1H3RXRAGPR119RORC | |
| SCHEMBL5548872 | 0.76 | POLB (0.40) | MAPK1NR1H2NR1H3RXRAGPR119 | |
| SCHEMBL6207940 | 0.74 | RIPK1 (0.46) | NR1H2NR1H3RXRAGPR119RORC | |
| SCHEMBL874416 | 0.74 | NR1H2 (0.49) | MAPK1NR1H2NR1H3RXRAGPR119 | |
| SCHEMBL4325057 | 0.74 | NR1H2 (0.49) | MAPK1NR1H2NR1H3RXRAGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191488-B1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2019-08-14 | — | — | EP | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118749-A1 | P2X7 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3191488-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | Janssen Pharmaceutica, N.V. (BE) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016039983-A1 | P2X7 MODULATING N-ACYL-TRIAZOLOPYRAZINES | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118749-A1 | P2X7 MODULATORS | P2RX7, P2RX3, P2RX1 | MAPK1 603/4885NR1H2 384/4885NR1H3 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.